{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:40:24Z","timestamp":1790703624617,"version":"4.1.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:00:00Z","timestamp":1552521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.00449","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T00:21:27Z","timestamp":1552522887000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":136,"title":["Complement in the Pathophysiology of the Antiphospholipid Syndrome"],"prefix":"10.3389","volume":"10","author":[{"given":"Shruti","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,3,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"B2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1055\/s-0038-1646476","article-title":"Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin","volume":"66","author":"Bevers","year":"1991","journal-title":"Thromb Haemost"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1182\/blood-2007-01-066043","article-title":"Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study","volume":"110","author":"Galli","year":"2007","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1073\/pnas.87.11.4120","article-title":"Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H)","volume":"87","author":"McNeil","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1182\/blood-2010-08-300715","article-title":"Beta(2)-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model","volume":"117","author":"Arad","year":"2011","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1160\/TH12-07-0527","article-title":"Prevalence of antibodies to prothrombin in solid phase (aPT) and to phosphatidylserine-prothrombin complex (aPS\/PT) in patients with and without lupus anticoagulant","volume":"109","author":"Bertolaccini","year":"2013","journal-title":"Thromb Haemost"},{"key":"B7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1055\/s-0038-1648517","article-title":"Beta 2-glycoprotein I deficiency and the risk of thrombosis","volume":"67","author":"Bancsi","year":"1992","journal-title":"Thromb Haemost"},{"key":"B8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/0021-9150(85)90163-7","article-title":"Characterization of plasma lipids and lipoproteins in patients with beta 2-glycoprotein I (apolipoprotein H) deficiency","volume":"55","author":"Hoeg","year":"1985","journal-title":"Atherosclerosis"},{"key":"B9","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood.V74.7.2426.2426","article-title":"Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant","volume":"74","author":"Marciniak","year":"1989","journal-title":"Blood."},{"key":"B10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1177\/0961203309360841","article-title":"Antiphospholipid antibodies and the protein C pathway","volume":"19","author":"Urbanus","year":"2010","journal-title":"Lupus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/j.1365-2141.2006.06385.x","article-title":"Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants","volume":"136","author":"Liest\u00f8l","year":"2007","journal-title":"Br J Haematol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.24262","article-title":"Beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation","volume":"60","author":"Bu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2004-05-1708","article-title":"Annexin A2 mediates endothelial cell activation by antiphospholipid\/anti-beta2 glycoprotein I antibodies","volume":"105","author":"Zhang","year":"2005","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1002\/art.21968","article-title":"Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V","volume":"54","author":"Shi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1002\/art.22802","article-title":"Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts","volume":"56","author":"Sorice","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1055\/s-0037-1599081","article-title":"Extracellular vesicles in the antiphospholipid syndrome","volume":"44","author":"Chaturvedi","year":"2018","journal-title":"Semin Thromb Hemost"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1016\/0002-9378(94)90403-0","article-title":"Reduction of annexin-V (placental anticoagulant protein-I) on placental villi of women with antiphospholipid antibodies and recurrent spontaneous abortion","volume":"171","author":"Rand","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1177\/0961203312458839","article-title":"C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies","volume":"21","author":"Carrera-Mar\u00edn","year":"2012","journal-title":"Lupus"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2005-03-1319","article-title":"Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor","volume":"106","author":"Fischetti","year":"2005","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1182\/blood-2013-11-537704","article-title":"A non-complement-fixing antibody to beta2 glycoprotein I as a novel therapy for antiphospholipid syndrome","volume":"123","author":"Agostinis","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J Clin Invest"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","article-title":"Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury","volume":"110","author":"Redecha","year":"2007","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.3389\/fimmu.2018.01388","article-title":"Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications","volume":"9","author":"Tedesco","year":"2018","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4794","DOI":"10.4049\/jimmunol.177.7.4794","article-title":"A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways","volume":"177","author":"Ritis","year":"2006","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e1326442","DOI":"10.1080\/2162402X.2017.1326442","article-title":"Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy","volume":"6","author":"Facciabene","year":"2017","journal-title":"Oncoimmunology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ekir.2016.08.015","article-title":"Complement activation induces neutrophil adhesion and neutrophil-platelet aggregate formation on vascular endothelial cells","volume":"2","author":"Riedl","year":"2017","journal-title":"Kidney Int Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.kint.2016.03.023","article-title":"Von Willebrand factor regulates complement on endothelial cells","volume":"90","author":"Noone","year":"2016","journal-title":"Kidney Int"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1182\/blood-2016-11-749879","article-title":"Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development","volume":"129","author":"Subramaniam","year":"2017","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1172\/JCI36089","article-title":"Neutrophil activation by the tissue factor\/Factor VIIa\/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome","volume":"118","author":"Redecha","year":"2008","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(11)90700-5","article-title":"Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB\/c mice: a model for autoimmune fetal loss","author":"Branch","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1182\/blood-2011-01-333617","article-title":"In vivo distribution of beta2 glycoprotein I under various pathophysiologic conditions","volume":"118","author":"Agostinis","year":"2011","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/1529-0131(200001)43:1<140::AID-ANR18>3.0.CO;2-P","article-title":"Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I","volume":"43","author":"Di Simone","year":"2000","journal-title":"Arthritis Rheum"},{"key":"B36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1084\/jem.200116116","article-title":"Complement C3 activation is required for antiphospholipid antibody-induced fetal loss","volume":"195","author":"Holers","year":"2002","journal-title":"J Exp Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.molimm.2004.07.043","article-title":"A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice","volume":"42","author":"Thurman","year":"2005","journal-title":"Mol Immunol"},{"key":"B38","first-page":"80","article-title":"Antiphospholipid antibodies in systemic lupus erythematosus: evidence of an association with positive Coombs' and hypocomplementemia","volume":"15","author":"Hazeltine","year":"1988","journal-title":"J Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1160\/TH11-08-0554","article-title":"Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb Haemost"},{"key":"B41","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1177\/0961203312444172","article-title":"Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome","volume":"21","author":"De Carolis","year":"2012","journal-title":"Lupus"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1093\/rheumatology\/kes225","article-title":"Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?","volume":"51","author":"Reggia","year":"2012","journal-title":"Rheumatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1136\/annrheumdis-2017-212224","article-title":"Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and\/or antiphospholipid antibodies","volume":"77","author":"Kim","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/path.2893","article-title":"Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss","volume":"225","author":"Cohen","year":"2011","journal-title":"J Pathol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"167.e161","DOI":"10.1016\/j.ajog.2006.10.879","article-title":"Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies","volume":"196","author":"Shamonki","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1196\/annals.1361.083","article-title":"Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome","volume":"1051","author":"Pierangeli","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1084\/jem.182.6.1807","article-title":"Complement-mediated regulation of tissue factor activity in endothelium","volume":"182","author":"Saadi","year":"1995","journal-title":"J Exp Med"},{"key":"B48","first-page":"455","article-title":"Antiphospholipid antibodies and complement activation in patients with cerebral ischemia","volume":"10","author":"Davis","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1160\/TH10-06-0410","article-title":"Is there an association between complement activation and antiphospholipid antibody-related thrombosis?","volume":"104","author":"Devreese","year":"2010","journal-title":"Thromb Haemost"},{"key":"B50","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1093\/rheumatology\/kew040","article-title":"Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome","volume":"55","author":"Barratt-Due","year":"2016","journal-title":"Rheumatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B55","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.semarthrit.2011.05.007","article-title":"HELLP syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies","volume":"41","author":"Appenzeller","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"B56","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1182\/bloodadvances.2018017095","article-title":"Complement C5 but not C3 is expendable for tissue factor activation by cofactor-independent antiphospholipid antibodies","volume":"2","author":"Muller-Calleja","year":"2018","journal-title":"Blood Adv"},{"key":"B57","doi-asserted-by":"publisher","first-page":"704371","DOI":"10.1155\/2014\/704371","article-title":"36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature","volume":"2014","author":"Strakhan","year":"2014","journal-title":"Case Rep Hematol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/rheumatology\/kev371","article-title":"A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor","volume":"55","author":"Wig","year":"2016","journal-title":"Rheumatology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e6338","DOI":"10.1097\/MD.0000000000006338","article-title":"Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: a case report","volume":"96","author":"Gustavsen","year":"2017","journal-title":"Medicine"},{"key":"B60","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/jth.13257","article-title":"Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study","volume":"14","author":"Marchetti","year":"2016","journal-title":"J Thromb Haemost."},{"key":"B61","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/RHU.0000000000000290","article-title":"Eculizumab induces sustained remission in a patient with refractory primary catastrophic antiphospholipid syndrome","volume":"21","author":"Zikos","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"de Groot","year":"2005","journal-title":"J Thromb Haemost"},{"key":"B63","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S1474-4422(09)70239-X","article-title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study","volume":"8","author":"Urbanus","year":"2009","journal-title":"Lancet Neurol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.blre.2010.12.001","article-title":"Antiphospholipid antibodies\u2013we are not quite there yet","volume":"25","author":"Urbanus","year":"2011","journal-title":"Blood Rev"},{"key":"B65","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1373\/clinchem.2009.133678","article-title":"Challenges in the diagnosis of the antiphospholipid syndrome","volume":"56","author":"Devreese","year":"2010","journal-title":"Clin Chem"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"Beta(2)-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood"},{"key":"B67","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1172\/JCI200421075","article-title":"Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes","volume":"114","author":"Trouw","year":"2004","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1046\/j.1365-2249.1997.d01-973.x","article-title":"Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti-phospholipid syndrome (APLS)","volume":"108","author":"Arfors","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.1780401112","article-title":"Anticardiolipin IgG subclasses: association of IgG2 with arterial and\/or venous thrombosis","volume":"40","author":"Sammaritano","year":"1997","journal-title":"Arthritis Rheum"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/rheumatology\/40.9.1026","article-title":"IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations","volume":"40","author":"Samarkos","year":"2001","journal-title":"Rheumatology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1177\/0961203311411597","article-title":"Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers","volume":"20","author":"Akhter","year":"2011","journal-title":"Lupus."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s10067-012-2017-1","article-title":"Anti-C1q antibody is a valuable biological marker for prediction of renal pathological characteristics in lupus nephritis","volume":"31","author":"Chen","year":"2012","journal-title":"Clin Rheumatol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1093\/rheumatology\/kew196","article-title":"Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis\/pregnancy morbidity in anti-phospholipid syndrome","volume":"55","author":"Oku","year":"2016","journal-title":"Rheumatology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.molimm.2014.02.012","article-title":"A potential anti-coagulant role of complement factor H","volume":"59","author":"Ferluga","year":"2014","journal-title":"Mol Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3899\/jrheum.150185","article-title":"Factor H autoantibodies in patients with antiphospholipid syndrome and thrombosis","volume":"42","author":"Foltyn Zadura","year":"2015","journal-title":"J Rheumatol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"R185","DOI":"10.1186\/ar4016","article-title":"Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome","volume":"14","author":"Foltyn Zadura","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"B77","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.thromres.2018.02.142","article-title":"Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome","volume":"164","author":"Nakamura","year":"2018","journal-title":"Thromb Res"},{"key":"B78","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1055\/s-0038-1655974","article-title":"C5a induces tissue factor activity on endothelial cells","volume":"77","author":"Ikeda","year":"1997","journal-title":"Thromb Haemost"},{"key":"B79","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.thromres.2004.06.012","article-title":"Mechanisms of autoantibody-induced monocyte tissue factor expression","volume":"114","author":"Wolberg","year":"2004","journal-title":"Thromb Res"},{"key":"B80","doi-asserted-by":"crossref","first-page":"9053","DOI":"10.1016\/S0021-9258(18)81901-9","article-title":"Complement proteins C5b-9 induce secretion of high molecular weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface","volume":"264","author":"Hattori","year":"1989","journal-title":"J Biol Chem"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1172\/JCI117430","article-title":"C5a-induced expression of P-selectin in endothelial cells","volume":"94","author":"Foreman","year":"1994","journal-title":"J Clin Invest"},{"key":"B82","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/S0021-9258(19)39666-8","article-title":"Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex","volume":"265","author":"Hamilton","year":"1990","journal-title":"J Biol Chem"},{"key":"B83","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.thromres.2014.02.023","article-title":"Studies of fibrin formation and fibrinolytic function in patients with the antiphospholipid syndrome","volume":"133","author":"Vikerfors","year":"2014","journal-title":"Thromb Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11926-009-0075-4","article-title":"Impaired fibrinolysis in the antiphospholipid syndrome","volume":"12","author":"Krone","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.thromres.2017.06.028","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS)","volume":"158","author":"Grosso","year":"2017","journal-title":"Thromb Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nm1419","article-title":"Generation of C5a in the absence of C3: a new complement activation pathway","volume":"12","author":"Huber-Lang","year":"2006","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ebiom.2016.02.011","article-title":"Complement activation in arterial and venous thrombosis is mediated by plasmin","volume":"5","author":"Foley","year":"2016","journal-title":"EBioMed"},{"key":"B88","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"key":"B89","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jaut.2009.02.008","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the \u201cCAPS Registry\u201d","volume":"32","author":"Cervera","year":"2009","journal-title":"J Autoimmun"},{"key":"B90","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.placenta.2012.11.014","article-title":"Eculizumab for the treatment of preeclampsia\/HELLP syndrome","volume":"34","author":"Burwick","year":"2013","journal-title":"Placenta"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/HYPERTENSIONAHA.113.01420","article-title":"Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy","volume":"62","author":"Burwick","year":"2013","journal-title":"Hypertension"},{"key":"B92","doi-asserted-by":"publisher","first-page":"99128","DOI":"10.1172\/jci.insight.99128","article-title":"Germline mutations in the alternative pathway of complement predispose to HELLP syndrome","volume":"3","author":"Vaught","year":"2018","journal-title":"JCI Insight"},{"key":"B93","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.imbio.2014.11.003","article-title":"Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn","volume":"220","author":"Hallstensen","year":"2015","journal-title":"Immunobiology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1097\/MD.0000000000000143","article-title":"Efficacy of eculizumab in apatient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report","volume":"93","author":"Kronbichler","year":"2014","journal-title":"Medicine"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e12584","DOI":"10.1097\/MD.0000000000012584","article-title":"Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: a case report","volume":"97","author":"Rovere-Querini","year":"2018","journal-title":"Medicine (Baltimore)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00449\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T15:57:49Z","timestamp":1663084669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.00449\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,14]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2019.00449"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.00449","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,14]]},"article-number":"449"}}